This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccm.2005.02.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology and clinical outcomes in skin and soft tissue nontuberculous mycobacteria infections: A retrospective study.
J Infect Public Health
January 2025
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:
Background: Nontuberculous mycobacteria (NTM) are emerging pathogens responsible for increasing skin and soft tissue infections (SSTIs) globally. However, the diagnosis and treatment of NTM SSTIs face significant challenges due to the lack of standardized guidelines. This study reviewed the clinical characteristics, diagnostic challenges, and treatment outcomes of NTM SSTIs in a large cohort from a tertiary referral center in Beijing, China.
View Article and Find Full Text PDFScreening, Discovery, and Optimization of the Natural Antitubercular Chlorflavonin from a Marine-Derived Fungal Library.
J Nat Prod
January 2025
Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
Tuberculosis (TB), caused by the bacterium (), is still a leading cause of mortality worldwide. Fifty-fungi from a marine-derived fungal library were screened for anti- activity, and an strain with strong anti- activity was found. Three known flavones, chlorflavonin (), dechlorflavonin (), and bromoflavone (), were isolated from this fungus.
View Article and Find Full Text PDFTargeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives.
Arch Microbiol
January 2025
Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
Tuberculosis (TB) remains a major global threat, with 10 million new cases and 1.5 million deaths each year. In multidrug-resistant tuberculosis (MDR-TB), resistance is most commonly observed against isoniazid (INH) and rifampicin (RIF), the two frontline drugs.
View Article and Find Full Text PDFLarge-scale production of infective larvae from engorged .
Front Trop Dis
December 2024
Parasite and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Background: is transmitted by species and affects hundred millions of inhabitants in about 33 countries in sub-Saharan Africa. It is known that Mansonellosis due to do not result in a clear clinical picture, but down-regulates the immunity of patients predisposing them to other diseases like tuberculosis, HIV and malaria or damping vaccine efficacy. However, research about novel drugs against this filarial nematode is missing because of the lack of parasite material.
View Article and Find Full Text PDFTotal hip arthroplasty in hip tuberculosis: a systematic review.
BMC Musculoskelet Disord
January 2025
Department of Joint Surgery, The Second Hospital of Jilin University, Changchun, 130,000, Jilin Province, China.
Objectives: Tuberculosis of the hip joint is a common form of bone tuberculosis that can cause severe joint destruction and affect quality of life. Total hip arthroplasty (THA) is an important way to treat hip joint-related diseases. In recent years, THA has been applied to treat tuberculosis of the hip joint and has achieved certain results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!